The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
- 05.01.2022
- Original Article
Erschienen in:
- Verfasst von
- Carlos Zamora Atenza
- Geòrgia Anguera
- Mariona Riudavets Melià
- Letícia Alserawan De Lamo
- Ivana Sullivan
- Andrés Barba Joaquin
- Jorgina Serra Lopez
- M. Angels Ortiz
- Maria Mulet
- Sílvia Vidal
- Margarita Majem
- Erschienen in
- Cancer Immunology, Immunotherapy | Ausgabe 8/2022
Abstract
Background
Tumor PD-L1 expression is a predictive biomarker for patients with NSCLC receiving PD-(L)1 blockade agents. However, although increased tumor PD-L1 expression predicts responsiveness, clinical benefit has been observed regardless of tumor PD-L1 expression, suggesting the existence of other PD-L1 sources. The aim of our study was to analyze whether integrating systemic and tumor PD-L1 is more predictive of efficacy in patients with advanced NSCLC receiving PD-(L)1 blockade agents.
Material and methods
Twenty-nine healthy donors and 119 consecutive patients with advanced NSCLC treated with PD-(L)1 drug were prospectively included. Pretreatment blood samples were collected to evaluate PD-L1 levels on circulating immune cells, platelets (PLTs), platelet microparticles (PMPs), and the plasma soluble PD-L1 concentration (sPD-L1). Tumor PD-L1 status was assessed by immunohistochemistry. The percentages of circulating PD-L1 + leukocytes, sPD-L1 levels, and tumor PD-L1 were correlated with efficacy.
Results
No differences in the percentages of circulating PD-L1 + leukocytes were observed according to tumor PD-L1 expression. Significantly longer progression-free survival was observed in patients with higher percentages of PD-L1 + CD14 + , PD-L1 + neutrophils, PD-L1 + PLTs, and PD-L1 + PMPs and significantly longer overall survival was observed in patients with higher percentages of PD-L1 + CD14 + and high tumor PD-L1 expression. Integrating the PD-L1 data of circulating and tumor PD-L1 results significantly stratified patients according to the efficacy of PD-(L1) blockade agents.
Conclusions
Our results suggest that integrating circulating PD-L1 + leukocytes, PLT, PMPs, and sPD-L1 and tumor PD-L1 expression may be helpful to decide on the best treatment strategy in patients with advanced NSCLC who are candidates for PD-(L)1 blockade agents.
Anzeige
- Titel
- The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
- Verfasst von
-
Carlos Zamora Atenza
Geòrgia Anguera
Mariona Riudavets Melià
Letícia Alserawan De Lamo
Ivana Sullivan
Andrés Barba Joaquin
Jorgina Serra Lopez
M. Angels Ortiz
Maria Mulet
Sílvia Vidal
Margarita Majem
- Publikationsdatum
- 05.01.2022
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Cancer Immunology, Immunotherapy / Ausgabe 8/2022
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851 - DOI
- https://doi.org/10.1007/s00262-021-03107-y
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
